Pierre Geborek
61 – 80 of 135
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Rapid and sustained health utility gain in anti-TNF treated inflammatory arthritis. Observational data during seven years in southern Sweden.
(
- Contribution to journal › Article
-
Mark
Presence of peripheral arthritis and male sex predicting continuation of anti–tumor necrosis factor therapy in ankylosing spondylitis: An observational prospective cohort study from the South Swedish arthritis treatment group register
(
- Contribution to journal › Article
-
Mark
Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics.
(
- Contribution to journal › Article
-
Mark
Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study.
(
- Contribution to journal › Article
- 2009
-
Mark
Measures and time points relevant for post-surgical follow-up in patients with inflammatory arthritis: a pilot study
(
- Contribution to journal › Article
-
Mark
Geriatric rheumatoid arthritis patients on delayed anti-TF-alpha agents have higher disease activity and experience more often serious adverse events compared to younger adults
(
- Contribution to journal › Published meeting abstract
-
Mark
Studies of mechanisms underlying the prolonged neutrophil survival in ANCA-associated systemic vasculitis
(
- Contribution to journal › Published meeting abstract
-
Mark
Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data
(
- Contribution to journal › Article
-
Mark
Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden
(
- Contribution to journal › Article
-
Mark
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas:relative risks and time-trends in the Swedish Biologics Register
(
- Contribution to journal › Article
-
Mark
Disease activity level, remission and response in established rheumatoid arthritis: Performance of various criteria sets in an observational cohort, treated with anti-TNF agents
(
- Contribution to journal › Article
-
Mark
Differences in Longitudinal Disease and Treatment Characteristics of Patients with Rheumatoid Arthritis Replying and Not Replying to a Postal Questionnaire. Experience from a Biologics Register in Southern Sweden.
(
- Contribution to journal › Article
-
Mark
Six and 12 Weeks Treatment Response Predicts Continuation of Tumor Necrosis Factor Blockade in Rheumatoid Arthritis: An Observational Cohort Study from Southern Sweden.
(
- Contribution to journal › Article
-
Mark
Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register.
(
- Contribution to journal › Article
-
Mark
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
(
- Contribution to journal › Article
-
Mark
Long-term follow-up of RA patients of the Hellenic Biologics Registry: comparison of first versus second anti-TNF-alpha therapy
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Efficacy and tolerability of anti-TNF therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article
-
Mark
Why do women with early RA respond less well to MTX than men? Gender as a determinant of response in the initial phase of the Swefot trial
(
- Contribution to journal › Published meeting abstract
-
Mark
The Swedish biologics register (ARTIS): observations of adverse events when using biologics in clinical practice
(
- Contribution to journal › Published meeting abstract
-
Mark
Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article